シノバスとスティフェルはGMEDの株を拡大し,収益は63.1%増加し,GEHCは収益予測を上回った. Synovus and Stifel increased stakes in GMED, which saw a 63.1% revenue jump, while GEHC also beat earnings estimates.

Synovus Financial Corpは、第3四半期にGlobus Medical(GMED)の株式を9.8%増やし、Stifel Financial Corpも持ち株を増やしました。 Synovus Financial Corp increased its stake in Globus Medical (GMED) by 9.8% in the third quarter, while Stifel Financial Corp also boosted its holdings. GMEDは6.1%の収入増加,EPSは0.83の見積りを報告した. GMED reported a 63.1% revenue increase and an EPS of $0.83, beating estimates. 分析官は"モデレート・バイヤー"の合意を得ており,平均約92.18ドルを目標にしている. Analysts have a "Moderate Buy" consensus, with a $92.18 average target price. 一方 機関投資家は GE HealthCare Technologies (GEHC) のポジションを調整し アナリストの評価と価格目標が変化した. Meanwhile, institutional investors adjusted their positions in GE HealthCare Technologies (GEHC), with varied analyst ratings and price targets. GEHCのQ3収益率の見積りで,同社は0.035ドルの四分の一の配当を宣言した. GEHC's Q3 earnings beat estimates, and the company declared a quarterly dividend of $0.035.